Transcript Hepatitis A
Viral Hepatitis
Hugh B. Fackrell
Filename: Hepatite.ppt
4/9/2015
1
Hepatitis Virus Outline
2
Definitions
Classification
Structure
Multiplication
Clinical manifestations
Epidemiology
Diagnosis
Control
Baron’s Web Site
4/9/2015
Hepatitis
an ancient disease, the etiology has only
recently (50 yrs.) been revealed.
4/9/2015
3
Hepatitis
An inflammatory disease
necrosis
of hepatocytes
mononuclear response destroys liver architecture
Liver excretion of bile pigments such as bilirubin
into the intestine is interrupted
4/9/2015
4
Bilirubin
Bilirubin: greenish-yellow pigment
accumulates in the blood and tissues
Jaundice
yellow tinge in the skin and eyes
caused
by bilirubin
4/9/2015
5
Types of Jaundice
Pre hepatic: Hemolytic Jaundice
normal
feces, anemia, reticulocytes
Hepatic: Hepatocellular Jaundice
fecal fat, bilirubinuria, Alkaline phosphatase
high, gamma globulins high
Post Hepatic: Obstructive Jaundice
fecal
fat, bilirubinuria, alkaline phosphatase
high
4/9/2015
6
Jaundice of the Newborn
Premature infants
bilirubin increases from birth
peaks at one week
caused by
1:excessive
hemolysis
2:immature liver function
4/9/2015
7
Hepatitis symptoms
8
Swelling and
tenderness of liver
Jaundice -yellow
tinge in the skin and
eyes
dark urine
transaminase, alkaline
phosphatase levels
increased
4/9/2015
Viral Hepatitis
Liver infection caused by several
UNRELATED VIRUSES
Inflammation and necrosis of the liver
50% of HAV & HBV are subclincal
4/9/2015
9
Hepatitis types
Hepatitis A - HAV "infectious hepatitis"
Hepatitis B - HBV "serum hepatitis"
Hepatitis C - HCV non A, non B
Hepatitis D - HDV Delta virus
Hepatitis E - HEV similar to type “A”
4/9/2015
10
Hepatitis A
“Infectious hepatitis”
“Epidemic hepatitis”
HAV
4/9/2015
11
Hepatitis A
Clinical manifestations
asymptotic or anicteric in children
3-5 week incubation period
liver inflammation
malaise - flu like symptoms
self limiting
low mortality
4/9/2015
12
Hepatitis A
Structure
Picornavirus
Only one serotype
Enterovirus type 72
27-29 nm icosahedral
ssRNA
4/9/2015
13
Hepatitis A
Host Defenses
antibodies develop late in incubation period
IgM
within
a week of dark urine
peaks a week later
lasts 40-60 days
IgG
after
14
IgM
peaks 60-80 days
lasts many years
4/9/2015
Hepatitis A
Epidemiology
Global distribution- underreported
Fecal-oral route,
person
to person
water
Overcrowding & poor sanitation
Infected food handlers common vector
4/9/2015
15
Annual Incidence Viral food
borne diseases
Norwalk-like viruses Total Viral food borne
30,883,391
23,000,000
Total Microbial food
Rotavirus
borne incidence
3,900,000
Astrovirus
38,629,64
3,900,000
Hepatitis A
83,391
CDC
4/9/2015
16
Hepatitis A
Diagnosis
Clinical manifestions
Viral antigens
Immunoelectron
microscopy
RIA
ELISA
Immune Adherence
hemagglutination (old
method)
Viral antibodies
4/9/2015
17
Hepatitis A
Control
No specific control
Improve hygiene and sanitation
Human immunoglobulin
2
IU anti Hepatitis A /kg body weight
HAV vaccines in clinical field trials
4/9/2015
18
Hepatitis B
“Serum hepatitis”
HBV
4/9/2015
19
Hepatitis B
Clinical Manifestations
typical viral hepatitis symptoms
4-26 week incubation period
more severe than HAV
CHRONIC PERSISTENT HEPATITIS
CHRONIC ACTIVE HEPATITIS
4/9/2015
20
Hepatitis B
Structure
Hepadnavirus
dsDNA, circular, 3200 nucleotides
enveloped icosahedral virus
42 nm
4/9/2015
21
Australia antigen
“Dane particle”
small pelomorphic particles 20-22nm
tubular forms
excess viral capsids released into blood
stream
4/9/2015
22
3 forms of HBV
4/9/2015
23
Dane Particles
4/9/2015
24
Hepatitis B
Host Defenses
Cell mediated Immunity
important
for recover in acute phase
autoimmune liver damage in chronic infections
Humoral Immunity
not
always protective
HBsAg for Vaccines
Interferon
not
25
detected during infection
exogenous application effective
4/9/2015
Hepatitis B
Epidemiology
Parenterally ie via blood, saliva, menstrual
and vaginal discharges, semen and breast
milk
infected blood and blood products
sexual contact
perinatally from mother to child
4/9/2015
26
Hepatitis B
Prevalence
AREA
Western Europe
USA
Eastern Europe
USSR
China
Asia
HBsAg
0.2-0.5%
anti HBsAg
4-6%
2-7 %
20-55%
8-20 %
70-95%
4/9/2015
27
Hepatitis B
Diagnosis
Electron microscopy
Viral DNA polymerase
Viral DNA probes
Serology
4/9/2015
28
Hepatitis B
Serology
Hepatitis B surface antigen- HBsAg
10 subtypes
Hepatitis B core antigen- HBsCAg
Soluble core associated antigen HBeAg
Corresponding antibodies to
each antigen occur
4/9/2015
29
Hepatitis B
Control
No specific control
Passive Immunization
HBV immunoglobulin
250-500 IU within 48 hours
neonates of infected mothers -immediately after
birth
Active Immunization
HBsAg
30
recombinant
DNA in yeast
4/9/2015
HBV & Cancer
1. Transformation of the cell by virus
2. Helper virus if the transforming virus is
defective
3. Co-carcinogen, chemical, cigarette smoke
4/9/2015
31
Transformed cells
lose contact inhibition
continue to divide
form random aggregations
can become invasive
Not warts: Papovavirus
4/9/2015
32
Primary Hepatocellular Carcinoma
Highest incidence:
Central Africa
Southeast
China
Pacific Islands, Borneo, Sarawak, Taiwan
Icteric symptoms:
jaundice,
dark urine, pale stools
Global 250,000- 1,000,000 deaths /year
U.S.A. 5000 deaths / year
4/9/2015
33
Acute HBV & Cancer
Acute Hepatitis B
90%
1%
Resolution
Fulminant Hepatitis
Resolution
Asymptomatic
Carrier
Chronic Active
Hepatitis
Chronic
50%
Extrahepatic
Disease
Cirrhosis
Hepatic
Cell Carcinoma
4/9/2015
34
Hepatitis C
HCV
Non -A Non-B
4/9/2015
35
Hepatitis C
Clinical Manifestations
resembles HBV
persistent carrier state
50% of patients have chronic liver damage
associated with hepatocellular carcinoma
4/9/2015
36
Hepatitis C
is probably caused by several
different viruses
4/9/2015
37
Hepatitis C
Epidemiology
in USA causes 90% of post transfusion
hepatitis
Mother to infant transmission
4/9/2015
38
Hepatitis C
Diagnosis
C100-3 recombinant viral antigen
anti c100-3 marker of chronic infection
4/9/2015
39
Hepatitis A
HAV
Hepatitis B
HBV
Hepatitis C
HCV
Structure
RNA
DNA
HBV
Cultured in cells
yes
no
no
Epidemiology
endemic & epidemic
endemic
endemic
Transmission
oral/fecal,
water & food
blood/serum,
close contact
blood/serum,
intimate contact
2-7 weeks
1-6 months
2-8 weeks
fever, G-I tract disorder
fever, rash, arthritis
similar to HBV
Jaundice
1 case in 10
common
common
Onset
acute/short
gradual/chronic
acute/chronic
not available
yes
not available
yes
yes
yes
Incubation period
Symptoms
Vaccine
Diagnostic tests
4/9/2015
40
Hepatitis D
HDV
4/9/2015
41
Hepatitis D
Dependovirus, it is defective and cannot
produce infection unless the cell is also
infected with HBV.
Viroid - a naked strand of RNA that enters
the cell in piggy-back fashion.
4/9/2015
42
Hepatitis D
Clinical Manifestations
Dual infection is more severe than HBV
fulminating hepatitis
severe rapidly progressive hepatitis
severe exacerbations
4/9/2015
43
Hepatitis D
Structure
35-37 nm virus particle
shares coat protein of HBV
small RNA genome
one serotype
4/9/2015
44
Hepatitis D
Epidemiology
hemophiliacs and IV drug users
Contaminated blood and blood products
4/9/2015
45
Geographic distribution of HDV
4/9/2015
46
Hepatitis D
Diagnosis
Clinical manifestations
Delta antigen
Immunofluorescence
RIA
ELISA
Anti delta antigen
same
as above
4/9/2015
47
Hepatitis E Virus
4/9/2015
48
Hepatitis E
fecal/oral route
predominantly found in developing
countries but is world wide.
symptoms similar to HAV but mortality 12% (ten times that of Hepatitis A).
epidemics - India, Pakistan, Nepal, Burma,
North Africa and Mexico.
4/9/2015
49